Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1064"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_dose | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_value |
"0.000167"
|
| dc:creator | |
| dc:date |
"06/19/2009 20:22:02"
|
| ?:content |
"route of administration: oral
study duration: "The study was a randomized three-period cross-over design using a pair of Latin squares. Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval. Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast."
population: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes
ages: 20 - 34
C_max (day 4) @ 225mg/day venlafaxine: 167ng/mL
167ng/mL X 1g/10^9ng X 1000mL/1L = 0.000167g/L"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ venlafaxine_maximum_concentration_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1355 }